Complete Pathway Refactoring and Combinatorial Biosynthesis of Anthracyclines for Modulation of Histone Eviction and DNA Damage Bioactivities
Angewandte Chemie · 02.11.2026 · 138 (45)
DOI: 10.1002/ange.1050964 ↗Kurz gefasst
Fachartikel in der Zeitschrift Angewandte Chemie, online erschienen am 23.09.2026. Verfasst von Rongbin Wang und 15 weiteren Autor:innen. Die Arbeit nennt 97 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Science Foundation, National Institute of Food and Agriculture, National Center for Advancing Translational Sciences.
Abstract (Originalsprache)
Anthracyclines including doxorubicin are cornerstone chemotherapeutic agents with high cytotoxic potency, but their use in cancer treatment is limited by irreversible dose‐dependent cardiotoxicity. Recent investigations indicate that cardiotoxicity‐free anthracyclines may be achieved through uncoupling DNA damage from chromatin damage. However, semi‐synthetic derivatization is complicated by anthracycline structural complexity. Here, we report a modular synthetic biology platform for the complete refactoring and combinatorial biosynthesis of anthracyclines in Streptomyces coelicolor M1152Δ matAB . Using standardized synthetic DNA parts, we refactored three full biosynthetic pathways of nogalamycin (38 genes), doxorubicin (31 genes), and aclacinomycin (31 genes). The pathways were organized into four functional modules (aglycone biosynthesis, TDP‐carbohydrate formation, glycosylation, and tailoring reactions) to facilitate efficient reconstruction. The modular design facilitated streamlined combinatorial biosynthesis yielding 16 derivatives, including 13 novel analogs. Bioactivity profiling across human cancer cell lines identified six potent congeners. Their cytotoxicity correlated with in vitro DNA binding affinities. Two hit molecules harbored desired bioactivity profiles promoting histone eviction at a faster rate than doxorubicin, without causing DNA double strand breaks. Our approach highlights the power of synthetic biology in rational natural product engineering and provides a scalable strategy for exploring new and improved anthracycline anti‐cancer agents.
Förderung
- National Science Foundation
- National Institute of Food and Agriculture
- National Center for Advancing Translational Sciences
- Research Council of Finland
- Nederlandse Organisatie voor Wetenschappelijk Onderzoek
- Syöpäsäätiö
- Novo Nordisk Fonden
Zitieren
APA
Wang, R., Tirkkonen, H., Zanden, S. Y. V. D., Ponomareva, L., Fagon, I., Fève, L., Paige, K., Brown, C. L., Schwartz, N., Hecht, J., Nguyen, J., Thorson, J. S., Neefjes, J., Nybo, S. E., Shaaban, K. A., & Metsä‐Ketelä, M. (2026). Complete Pathway Refactoring and Combinatorial Biosynthesis of Anthracyclines for Modulation of Histone Eviction and DNA Damage Bioactivities. Angewandte Chemie, 138(45). https://doi.org/10.1002/ange.1050964
Vancouver
Wang R, Tirkkonen H, Zanden SYVD, Ponomareva L, Fagon I, Fève L, et al. Complete Pathway Refactoring and Combinatorial Biosynthesis of Anthracyclines for Modulation of Histone Eviction and DNA Damage Bioactivities. Angewandte Chemie. 2026;138(45). doi:10.1002/ange.1050964
BibTeX
@article{Wang2026,
author = {Wang, Rongbin and Tirkkonen, Heli and Zanden, Sabina Y. van der and Ponomareva, Larissa and Fagon, Isaline and Fève, Leslie and Paige, Kendall and Brown, Courtney L. and Schwartz, Nora and Hecht, Jacob and Nguyen, Jennifer and Thorson, Jon S. and Neefjes, Jacques and Nybo, S. Eric and Shaaban, Khaled A. and Metsä‐Ketelä, Mikko},
title = {Complete Pathway Refactoring and Combinatorial Biosynthesis of Anthracyclines for Modulation of Histone Eviction and DNA Damage Bioactivities},
journal = {Angewandte Chemie},
year = {2026},
volume = {138},
number = {45},
doi = {10.1002/ange.1050964}
}
EUVIMED